Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?
| Autor: | Run Huang, Yang Yu, Xiaolin Li, Huaiyu Weng, Lisi Ma, Xuan Chen, Sixuan Liu, Xiangyun Zong |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
endocrine system endocrine system diseases Cyclophosphamide medicine.medical_treatment Physiology 03 medical and health sciences 0302 clinical medicine Breast cancer Medicine Chemotherapy biology business.industry Anti-Müllerian hormone medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis biology.protein Biomarker (medicine) Amenorrhea medicine.symptom business Luteinizing hormone hormones hormone substitutes and hormone antagonists Hormone medicine.drug |
| Zdroj: | Cancer Management and Research. 12:8171-8181 |
| ISSN: | 1179-1322 |
| Popis: | Purpose The predictive value of anti-Mullerian hormone (AMH) for ovarian dysfunction postchemotherapy is controversial. This study aimed to evaluate the value of serum AMH levels clinically and theoretically. Patients animals and methods We detected the serum estradiol, follicular stimulating hormone (FSH), luteinizing hormone (LH), and AMH levels in 144 premenopausal women with breast cancer receiving cyclophosphamide-based chemotherapy. The hormone levels before and postchemotherapy were compared; the correlations among the hormones and amenorrhea and menstrual recovery were analyzed. In addition, the serum AMH levels were detected randomly in 177 normal healthy women and 36 normal female C57BL/6J mice of different ages; meanwhile, the status of ovarian follicles was also examined. Furthermore, 72 Balb/c nude mice with breast cancer were randomly assigned to three groups that received different doses of cyclophosphamide (CTX) (control, 100 mg/kg, and 200 mg/kg), and the alterations in serum AMH levels and ovarian follicles were recorded and analyzed. Results Chemotherapy-induced amenorrhea was associated with prechemotherapy AMH levels, E2 levels, and FSH levels (P 0.05). In patients with breast cancer treated with chemotherapy, the serum AMH levels did not differ significantly between the pre- and post-chemotherapy periods in patients aged 0.05), whereas a dramatic reduction was detected in patients aged >35 years (P Conclusion Our results indicate that AMH is an efficient marker for predicting postchemotherapy ovarian function exclusively in premenopausal female patients with breast cancer aged >35 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|